Jo Shorthouse

Jo Shorthouse

Executive Editor, In Vivo

Latest from Jo Shorthouse

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Rising Leaders 2025: Regeneron’s Karen Rodriguez Lorenc On Not Believing In Failure

Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approvals in Europe and the US. She talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.

Rising Leaders 2025: J&J’s June Lanoue On Working With A Cure In Mind

As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.